We are live on ! Find out more
BDSX icon

Biodesix

40 hedge funds and large institutions have $56.6M invested in Biodesix in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

411% more capital invested

Capital invested by funds: $11.1M → $56.6M (+$45.5M)

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

167% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 9

54% more funds holding

Funds holding: 2640 (+14)

19.1% more ownership

Funds ownership: 20.48%39.58% (+19%)

Holders
40
Holders Change
+14
Holders Change %
+53.85%
% of All Funds
0.49%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
24
Increased
6
Reduced
2
Closed
9
Calls
$215K
Puts
Net Calls
+$215K
Net Calls Change
+$130K

BDSX Hedge Fund Activity: Q1 2026 in Review

40 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Biodesix (BDSX) for Q1 2026, worth a combined $56.6M — up 411% from $11.1M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new BDSX positions and 9 closed out — a net gain of 15 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $9.4M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $764K sold.

  • 40 institutional investors held Biodesix (BDSX) as of Q1 2026, up from 26 in Q4 2025.
  • Funds reported $56.6M of Biodesix stock for Q1 2026, up 411% quarter-over-quarter.
  • 24 funds opened new Biodesix positions in Q1 2026 and 9 closed out, a net change of +15 holders.
  • The largest Biodesix buyer in Q1 2026 was AIGH Capital Management, an estimated $9.4M added.
  • The largest Biodesix seller in Q1 2026 was Monashee Investment Management, an estimated $764K sold.

Based on aggregated 13F filings for Q1 2026.